Positrigo AG Secures CE Mark for Revolutionary NeuroLF Brain PET System
Positrigo AG’s NeuroLF® system has received CE Mark approval, making it the first dedicated brain PET device approved in both the US and Europe. This portable imaging technology aids in diagnosing various brain disorders. The company plans to commercialize the device across Europe, addressing rising demands for amyloid PET imaging for Alzheimer’s diagnosis.
Positrigo AG, a Swiss company specializing in nuclear medical imaging, has secured the CE Mark for its innovative brain Positron Emission Tomography (PET) system, NeuroLF®. This landmark achievement follows FDA approval, making NeuroLF the first dedicated brain PET device approved in both the US and Europe. The system is designed for diagnosing and managing brain disorders, including Alzheimer’s disease, brain tumors, epilepsy, and Parkinson’s disease, offering a compact alternative to traditional hybrid PET systems. Medical experts highlight that this CE Mark represents a significant advancement, enabling nuclear medicine physicians in Europe to utilize a dedicated imaging modality for better patient diagnosis and monitoring. Positrigo aims to commercialize the NeuroLF system across Europe through partnerships with local companies to navigate the continent’s fragmented healthcare systems effectively. With increasing demand for amyloid PET imaging, particularly for early Alzheimer’s diagnosis, the NeuroLF system is poised to enhance PET imaging infrastructure throughout Europe. Positrigo was established in 2018 as a spin-off of ETH Zurich and is supported by private investors and government bodies. The NeuroLF scanner plays a key role in addressing the growing need for advanced imaging technologies in detecting brain disorders.
Positrigo AG is at the forefront of developing technologies for nuclear medical imaging, specifically focusing on brain applications. The approval of the NeuroLF system marks a pivotal moment in brain imaging, as it caters to the rising demand for precise diagnostic tools associated with neurodegenerative diseases. The CE Mark signifies compliance with European safety and efficacy standards, a critical step for companies looking to innovate within the medical devices sector.
In summary, Positrigo’s CE Mark approval for the NeuroLF system is a significant milestone, enhancing diagnostic capabilities for brain disorders in Europe. The device’s compact design and affordability offer a competitive alternative to existing systems, promising increased accessibility and improved patient outcomes in brain imaging.
Original Source: www.finanznachrichten.de